ReviewAsian Pacific journal of cancer prevention : APJCP2025
Virotherapy as Gene Deliver for Anti-Cancer Therapy: A Review Article.
Review in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review identifies Adenovirus (AdV) as a leading candidate for gene therapy due to its high transduction efficiency and large gene-carrying capacity, supported by evidence of its progression to phase III clinical trials. However, the interpretation of findings is limited by variations in study designs, potential publication bias, and possible exclusion of relevant studies. As the field continues to evolve with new vector technologies, future research should focus on improving vector safety, specificity, and long-term outcomes to maximize the therapeutic potential of virotherapy.
objectiveCancer is the second leading cause of death worldwide. Treatments like chemotherapy and radiotherapy are commonly used, but they have side effects and complications. Gene therapy, using viral vectors like retroviruses, Adenovirus (AdV), and Adeno-Associated Virus (AAV), offers a new approach to overcome these limitations by specifically targeting cancer cells' genetics. This article was developed as a review to compare the effectiveness of different viruses in virotherapy for cancer treatment.
methodsThis article employed a narrative literature review and qualitative content analysis to synthesize current knowledge on the topic. More than 85 peer-reviewed articles published between 2016 and 2024 were collected from databases such as ScienceDirect, PubMed, Scopus, and Nature. The search used relevant keywords with Boolean operators (AND, OR) to refine results. Articles were selected based on language (English), publication type (peer-reviewed), and relevance to the topic. The selected literature was analyzed to identify recurring patterns, key themes, and significant insights.
resultThe research results indicate that viruses demonstrated vary levels of efficacy. Retroviruses have a 40%-60% transduction efficiency, can integrate into the host genome, and infect only dividing cells. Adenovirus (AdV) has a 98% efficiency in hepatocellular carcinoma and 70%-80% in other cancers, delivers genetic material without integration, infects both dividing and non-dividing cells, and has a gene capacity of 37 kb. Adeno-Associated Virus (AAV) has a 30%-50% efficiency, a gene capacity of 4.8 kb, and also shows therapeutic potential.
conclusionEach virotherapy agent used in gene therapy exhibits varying efficacy against cancer cells, indicating specific mechanisms unique to each virotherapy agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.